Department of General, Oncological and Vascular Surgery, 5th Military Clinical Hospital in Krakow, Poland.
Department of Tumour Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Krakow Branch, Poland.
Pol J Pathol. 2022;73(1):60-71. doi: 10.5114/pjp.2021.115662.
This study aimed to compare prognostic potential of Nanog expression analysed by three immunohistochemical scores in the group of 63 squamous cell carcinomas of oropharynx. Immunoreactivity of Nanog expression was analyzed by semiquantitative score, immunoreactive score and H-score. For all three scores, the cut-off points for Nanog overexpression and its lack, allowing for optimal separation of overall and disease free survival curves, were search by minimal p-value method. In semiquantitative score, the best separation of overall and disease free survival curves was obtain by cut-off point lack of staining vs. week/moderate/strong staining, although statistical significance was not reach (OS: HR = 1.016, p = 0.081, DFS: HR = 6.876, p = 0.061). The cut-off points for immunoreactive score and H-score were, respectively: 1 (OS: HR = 6.977, p = 0.014, DFS: HR = 6.002, p = 0.019) and 50 (OS: HR = 6.977, p = 0.014, DFS: HR = 6.002, p = 0.019). The cut-off points found for these two scores allow to identify the same subgroups of patients with lack of Nanog expression (11.1%) and its overexpression (88.9%). All patients with tumors characterized by lack of Nanog overexpression identifying by immunoreactive score and H-score survived 5 years without evidence of cancer progression. In multivariate analysis Nanog immunoreactivity analysed by QRS and IRS was independent prognostic factor for OS (HR = 10.195, p = 0.024). Immunohistochemical score using to distinguish Nanog overexpression or its lack has influence on prognostic potential of this biomarker.
本研究旨在比较三种免疫组织化学评分分析的 Nanog 表达在 63 例口咽鳞状细胞癌患者中的预后价值。通过半定量评分、免疫反应评分和 H 评分分析 Nanog 表达的免疫反应性。对于所有三种评分，通过最小 p 值法搜索 Nanog 过表达和缺乏的最佳截断点，以便最佳分离总生存和无病生存曲线。在半定量评分中，通过无染色与弱/中/强染色的缺失来最佳分离总生存和无病生存曲线，尽管未达到统计学意义（OS：HR = 1.016，p = 0.081，DFS：HR = 6.876，p = 0.061）。免疫反应评分和 H 评分的截断点分别为：1（OS：HR = 6.977，p = 0.014，DFS：HR = 6.002，p = 0.019）和 50（OS：HR = 6.977，p = 0.014，DFS：HR = 6.002，p = 0.019）。这两个评分的截断点可以识别缺乏 Nanog 表达（11.1%）和过表达（88.9%）的相同患者亚组。所有免疫反应评分和 H 评分均缺乏 Nanog 过表达的肿瘤患者均在 5 年内无癌症进展证据而存活。在多变量分析中，QRS 和 IRS 分析的 Nanog 免疫反应性是 OS 的独立预后因素（HR = 10.195，p = 0.024）。用于区分 Nanog 过表达或缺乏的免疫组织化学评分对该生物标志物的预后价值有影响。
